Alnylam Pharmaceuticals (NASDAQ:ALNY) Releases Earnings Results, Beats Expectations By $14.60 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60, FiscalAI reports. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter last year, the company posted $2.90 earnings per share. The business’s quarterly revenue was up 16.7% on a year-over-year basis.

Here are the key takeaways from Alnylam Pharmaceuticals’ conference call:

• Q3 product revenue rose 52% year over year to approximately $1.3 billion, driven by AMVUTTRA and 59% growth in TTR revenue to $1.15 billion. Alnylam also ended the quarter with $3.6 billion in cash and marketable securities.
• Management expects 2026 TTR revenue at the low end of its $4.2 billion–$4.5 billion range, acknowledging that expanded commercial efforts have not yet translated into demand growth as quickly as anticipated. Potential fourth-quarter ordering volatility from the 340B rule and tighter UnitedHealth Medicare Advantage access may add pressure.
• Alnylam will expand the TRITON-CM study for nucresiran by 500 patients to approximately 2,250, primarily to account for potentially lower event rates as patients are diagnosed earlier and receive better background treatment. The company said the change is intended to improve statistical power and does not alter the expected ATTR cardiomyopathy launch timing of around 2030.
• Early brezosiran data in Huntington’s disease showed 60%–64% mean reductions in cerebrospinal-fluid mutant huntingtin, with reductions of up to 83% and no dose-dependent safety signals reported to date. Alnylam plans to advance the program toward a pivotal study in 2027, pending regulatory alignment.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY traded down $56.15 during trading on Thursday, reaching $176.25. The stock had a trading volume of 5,526,494 shares, compared to its average volume of 1,459,797. The stock has a fifty day simple moving average of $239.15 and a two-hundred day simple moving average of $288.34. Alnylam Pharmaceuticals has a 52 week low of $178.89 and a 52 week high of $479.79. The firm has a market capitalization of $23.58 billion, a price-to-earnings ratio of 32.86 and a beta of 0.28. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q3 results exceeded expectations: Alnylam reported earnings of $16.26 per share, well above consensus estimates ranging from $1.66 to $2.19. Revenue reached $1.46 billion, topping the $1.43 billion analyst forecast. Alnylam Pharmaceuticals Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Revenue growth remained solid: Quarterly revenue increased 16.7% from the prior-year period, while the company posted a 15.26% net margin and 84.93% return on equity. Alnylam Pharmaceuticals Earnings Report
• Positive Sentiment: Brezosiran data supports the bullish case: A recent analysis argued that ALNY could be substantially undervalued following clinical data for brezosiran, potentially providing an additional pipeline catalyst. Alnylam Could Be 39% Undervalued Following Brezosiran Data
• Neutral Sentiment: Trading was briefly halted: ALNY experienced a Limit Up-Limit Down pause shortly after the open, highlighting unusually sharp volatility around the earnings release.
• Negative Sentiment: Investors may have viewed the stock as fully valued: Commentary before earnings described ALNY as potentially “fully priced” after a 52% decline, which may have limited the market’s reaction to the earnings beat. Alnylam Stock Looks Fully Priced
• Negative Sentiment: The earnings beat may not fully ease concerns: The unusually large EPS result compared with $2.90 a year earlier could prompt investors to scrutinize the composition and repeatability of quarterly earnings, while shares remain near their 12-month low and below key moving averages.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the firm’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the sale, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. This trade represents a 12.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on ALNY. Stifel Nicolaus lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $225.00 price objective for the company. in a research note on Thursday. Barclays cut their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a report on Monday, August 3rd. Truist Financial lowered their target price on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. JPMorgan Chase & Co. reduced their target price on shares of Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating for the company in a research note on Wednesday, September 30th. Finally, Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $360.52.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.